Trial Profile
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X [fluticasone furoate] aqueous nasal spray 50mcg and 100mcg for 2 weeks in pediatric subjects ages 2 to 12 years with seasonal allergic rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GSK
- 01 Mar 2013 Planned patient number is 576 according to ClinicalTrials.gov.
- 06 Oct 2006 Status change
- 08 Oct 2005 New trial record.